PEDIATRICS Vol. 95 No. 2 February 1995, pp. 319
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitchell, I.
Right arrow Articles by Newth, C. J.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitchell, I.
Right arrow Articles by Newth, C. J.L.

Ribavirin. Red Book Committee Recommendations Questioned

Ian Mitchell MB, FRCPC1, Ari Joffe MD, FRCPC1, and C. J.L. Newth MB, FRCPC2

1 Alberta Children's Hospital and The University of Calgary, Calgary, Alberta, Canada T2T 5C7
2 Children's Hospital of Los Angeles, University of Southern California, Los Angeles, CA

We wrote this letter to comment on the recently published guidelines on the use of ribavirin for respiratory syncytial virus (RSV) infection,1 and to commend the commentary provided by Drs Wald and Dashefsky questioning these recommendations.2 In addition we point out the recent advertising campaign by ICN Canada where it is claimed that the Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) studies3,4 show "widespread underutilization" of ribavirin for RSV bronchiolitis,5 a conclusion not supported by detailed review of the literature.